Hepatitis B market getting heated

Published: 2007-09-27 06:58:00

Updated: 2007-09-27 06:58:00

Competition is about to heat up in the domestic antidiabetic market, as Bukwang Pharm's Levovir (clevudine) and BMS Korea's Baraclude (entecavir) are expanding its share of the domestic anti-hepatitis B market dominated by international drug makers.

Levovir's market share has captured 8.9 percent in the first quarter of this year and is challenging GlaxoSmithKline's Zeffix (lamivudine) and H...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.